Literature DB >> 3378958

The pharmacokinetics and tissue penetration of FCE 22101 following intravenous and oral administration.

J M Webberley1, R Wise, J M Andrews, J P Ashby, D Wallbridge.   

Abstract

One gram each of FCE 22101 and its acetoxymethyl ester (FCE 22891) were administered sequentially to six healthy volunteers. After intravenous administration Cmax was 167 mg/l, and the elimination half-life 0.8 h. Following oral administration Cmax was 6.9 mg/l and the elimination half-life 0.6 h. Penetration into inflammatory fluid was rapid, and the percentage penetration 86.1 and 60.9% following oral and intravenous dosing respectively. Urine recovery was greater after intravenous administration (31%) than after oral (11%).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3378958     DOI: 10.1093/jac/21.4.445

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Pharmacokinetics of [14C]FCE 22891, a penem antibiotic, following oral administration to healthy volunteers.

Authors:  C Efthymiopoulos; M Strolin Benedetti; D Sassella; A Boobis; D Davies
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

2.  Pharmacokinetics of FCE 22891, a new oral penem.

Authors:  A Saathoff; H Lode; B Hampel; K M Deppermann; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Pharmacokinetics of the penem CP-65,207 and its separate stereoisomers in humans.

Authors:  G Foulds; A K Knirsch; J D Lazar; T G Tensfelt; N Gerber
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

4.  Meropenem pharmacokinetics and penetration into an inflammatory exudate.

Authors:  R Wise; M Logan; M Cooper; J P Ashby; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

5.  Clinical and bacteriological efficacy and tolerability of FCE 22891 in patients with exacerbations of chronic obstructive pulmonary disease.

Authors:  W G Boersma; S M Puister; R van Altena; H G de Vries-Hospers; M Molinari; G H Koëter
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.